-
Notifications
You must be signed in to change notification settings - Fork 0
/
index.html
1396 lines (1296 loc) · 86.2 KB
/
index.html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
<!DOCTYPE html>
<html class="no-js" lang="en" dir="ltr">
<head>
<meta charset="utf-8">
<meta content="width=device-width,initial-scale=1" name="viewport">
<link rel="schema.dcterms" href="http://purl.org/dc/terms/">
<meta name="description" content="Information about any adverse events following immunization (AEFI) that individuals have reported after receiving a COVID-19 vaccine in Canada. These adverse events are not necessarily related to the vaccine.">
<meta name="keywords" content="coronavirus, covid-19, pandemic, Canada, vaccines covid, vaccines canada, vaccines covid, coronavirus vaccines, safety, side effects, adverse reaction, AEFI">
<meta name="author" content="Public Health Agency of Canada">
<meta name="dcterms.title" content="COVID-19 vaccine safety: Report on side effects following immunization">
<meta name="dcterms.description" content="Information about any adverse events following immunization (AEFI) that individuals have reported after receiving a COVID-19 vaccine in Canada. These adverse events are not necessarily related to the vaccine.">
<meta name="dcterms.creator" content="Public Health Agency of Canada">
<meta name="dcterms.language" title="ISO639-2/T" content="eng">
<meta name="dcterms.subject" title="gccore" content="HE Health and Safety">
<meta name="dcterms.issued" title="W3CDTF" content="2021-01-08">
<meta name="dcterms.modified" title="W3CDTF" content="2021-01-29">
<meta name="dcterms.spatial" content="Canada">
<meta name="dcterms.type" content="datasets;statistics;education and awareness">
<meta name="dcterms.source" content="aem">
<meta name="dcterms.identifier" content="Public_Health_Agency_of_Canada">
<meta prefix="fb: https://www.facebook.com/2008/fbml" property="fb:pages" content="378967748836213, 160339344047502, 184605778338568, 237796269600506, 10860597051, 14498271095, 209857686718, 160504807323251, 111156792247197, 113429762015861, 502566449790031, 312292485564363, 1471831713076413, 22724568071, 17294463927, 1442463402719857, 247990812241506, 730097607131117, 1142481292546228, 1765602380419601, 131514060764735, 307780276294187, 427238637642566, 525934210910141, 1016214671785090, 192657607776229, 586856208161152, 1146080748799944, 408143085978521, 490290084411688, 163828286987751, 565688503775086, 460123390028, 318424514044, 632493333805962, 370233926766473, 173004244677, 1562729973959056, 362400293941960, 769857139754987, 167891083224996, 466882737009651, 126404198009505, 135409166525475, 664638680273646, 169011506491295, 217171551640146, 182842831756930, 1464645710444681, 218822426028, 218740415905, 123326971154939, 125058490980757, 1062292210514762, 1768389106741505, 310939332270090, 285960408117397, 985916134909087, 655533774808209, 1522633664630497, 686814348097821, 230798677012118, 320520588000085, 103201203106202, 273375356172196, 61263506236, 353102841161, 1061339807224729, 1090791104267764, 395867780593657, 1597876400459657, 388427768185631, 937815283021844, 207409132619743, 1952090675003143, 206529629372368, 218566908564369, 175257766291975, 118472908172897, 767088219985590, 478573952173735, 465264530180856, 317418191615817, 428040827230778, 222493134493922, 196833853688656, 194633827256676, 252002641498535, 398018420213195, 265626156847421, 202442683196210, 384350631577399, 385499078129720, 178433945604162, 398240836869162, 326182960762584, 354672164565195, 375081249171867, 333050716732105, 118996871563050, 240349086055056, 119579301504003, 185184131584797, 333647780005544, 306255172770146, 369589566399283, 117461228379000, 349774478396157, 201995959908210, 307017162692056, 145928592172074, 122656527842056">
<title>COVID-19 vaccine safety: Report on side effects following immunization - Canada.ca</title>
<link rel="apple-touch-icon" sizes="57x57 72x72 114x114 144x144 150x150" class="wb-favicon" href="/src/GCWeb/assets/favicon-mobile.png"><link href="/src/GCWeb/assets/favicon.ico" rel="icon" type="image/x-icon" class="wb-init wb-favicon-inited">
<link href="/src/GCWeb/assets/favicon.ico" rel="icon" type="image/x-icon">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css">
<link rel="stylesheet" href="/src/GCWeb/css/wet-boew.min.css">
<link rel="stylesheet" href="/src/GCWeb/css/theme.min.css">
<noscript><link rel="stylesheet" href="/src/wet-boew/css/noscript.min.css"></noscript>
<style>
#bigGraph{
font-size:0.7em;
}
.circle {
display: inline-block;
float: left;
width: 15px;
height: 15px;
border-radius: 50%;
margin: 0 5px;
position: absolute;
top: 50%;
transform: translate(0, -50%);
}
.selection {
-webkit-user-select: none;
/* Safari */
-moz-user-select: none;
/* Firefox */
-ms-user-select: none;
/* IE10+/Edge */
user-select: none;
/* Standard */
margin: 0 1px;
position: relative;
width: 150px;
height: 40px;
font-size: 1em;
border: solid 2px rgba(150, 150, 150, 0.2);
cursor: pointer;
}
.selection p {
line-height: 20px;
margin-left: 22px;
display: inline;
position: absolute;
top: 50%;
transform: translate(0, -50%);
}
.selection:hover {
background-color: rgba(150, 150, 150, 0.2);
}
#displayPanel {
width: 100%;
display: -ms-grid;
display: grid;
-ms-grid-columns: 150px 1fr;
grid-template-columns: 150px auto;
}
#logPanel {
-ms-grid-column: 1;
-ms-grid-row: 1;
padding-bottom: 5px;
width: 100%;
display: flex;
justify-content: space-evenly;
}
#logPanel button {
height: 35px;
margin: 0;
}
#descPanel {
-ms-grid-column: 2;
-ms-grid-row: 1;
}
#descPanel p {
line-height: 20px;
font-size:0.9em;
margin:0;
text-align: center;
}
#descPanel span {
font-weight: bold;
}
#btnPanel {
-ms-grid-column-span:2;
-ms-grid-row:3;
grid-column: span 2;
padding: 0;
width: 100%;
display: flex;
flex-wrap: wrap;
justify-content: center;
}
#graphPanel {
-ms-grid-column:1;
-ms-grid-column-span:2;
-ms-grid-row:2;
grid-column: span 2;
grid-row: 2/3;
width: 100%;
}
#big {
width: 100%;
height: 300px;
}
#big .tick text {
font-size: 1.1em;
}
.tab {
overflow: hidden;
background-color: white;
color: #295376;
}
/* Style the buttons inside the tab */
.tab button {
background-color: inherit;
/*float: left;*/
border: none;
outline: none;
cursor: pointer;
padding: 2px 16px;
transition: 0.3s;
font-size: 17px;
color: #295376;
}
/* Change background color of buttons on hover */
.tab button:hover {
background-color: #ddd;
}
.tab button:focus {
border: 1px solid black;
}
/* Create an active/current tablink class */
.tab button.active {
background-color: #ccc;
}
/* Style the tab content */
.tabcontent {
display: none;
padding: 6px 12px;
border-top: none;
}
.bar {
fill: #015B7E;
stroke: #015B7E;
}
.axis {
stroke: #D8D8D8;
}
text {
/* fill: #6c686f; */
fill: black;
}
.tick>line,
.domain {
stroke: #ccc;
}
.x-axis-title,
.y-axis-title {
font-size: 0.8em;
}
.x-axis .tick line {
stroke: black;
}
.x-axis,
.y-axis {
font-size: 12px;
}
label {
display: inline;
}
.line {
fill: none;
stroke-width: 3px;
}
.chart rect {
stroke: black;
stroke-width: 0.09px;
}
/*dashboard */
#dashboard {
/*height: 90%;*/
}
/* Key numbers boxes */
.boxes {
text-align: center;
display: flex;
flex-wrap: wrap;
padding-left: 1px;
padding-right: 1px;
height: 10%;
justify-content: center;
}
.hiddenInfo {
border-radius: 10px;
}
.boxes .parent, .boxes .parent:visited, .boxes .parent:focus {
flex: 0 0 30%;
border: 3px solid #ccc;
border-radius: 10px;
margin: 10px;
text-decoration: none;
color: black;
}
.boxes .box {
text-decoration: none;
color: black;
}
.boxes .parent:hover {
border: 3px solid #000;
border-radius: 10px;
box-shadow: 2px 2px;
}
.innerBox {
flex: 0 0 23%;
border: 1px solid #ccc;
border-radius: 10px;
margin-left: 0px;
margin-right: 3px;
text-decoration: none;
color: black;
margin-bottom: 5px;
}
.innerBox div {
padding-left: 3px;
padding-right: 3px;
}
.boxes p {
font-size: 18px;
margin-top: 5px;
margin-bottom: 5px;
}
.boxes p.h2 {
font-size: 30px;
margin-top: 5px;
}
table {
border: 1.5px solid black;
}
.top{
margin-bottom: 10px;
}
td {
border: 1.5px solid black;
padding: 4px;
}
th {
border: 1.5px solid black;
padding: 5px;
}
/* Graph Panels */
#graphArea {
/*text-align: center;*/
display: flex;
flex-wrap: wrap;
justify-content: center;
padding-left: 0px;
padding-right: 0px;
}
.graphPanels {
flex: 0 0 47%;
margin: 10px;
text-decoration: none;
color: black;
margin-bottom: 5px;
padding-left: 10px;
padding-right: 10px;
border: 1px solid #ccc;
border-radius: 10px;
}
#graphHospital text,
#graphHospitalBySex text {
font-size: 16px;
}
#probable-exposure .y-axis,
#probable-exposure .x-axis,
#probable-exposure #legend {
font-size: 16px;
}
td#ratetested {
min-width: 80px;
}
td#numtested {
min-width: 113px;
}
#full:disabled{
background-color: #cccccc;
}
@media only screen and (max-width: 800px) {
#probable-exposure .y-axis,
#probable-exposure .x-axis,
#probable-exposure #legend {
font-size: 18px;
}
#hospitalization text {
font-size: 18px;
}
.x-axis-title,
.y-axis-title {
font-size: 1.1em!important;
}
.txtTotal {
white-space: nowrap;
}
.boxes .parent:visited, .boxes .parent:focus, .boxes .parent:hover {
flex: 0 0 37.5%;
border: 1px solid #ccc;
border-radius: 10px;
margin: 5px;
text-decoration: none;
color: black;
}
.boxes p{
font-size: 16px;
}
}
@media only screen and (max-width: 991px) {
.selection {
border-radius: 0;
}
#big {
height: 500px;
}
#btnPanel {
-ms-grid-column-span: 2;
-ms-grid-row: 3;
grid-column: span 2;
}
#graphPanel {
-ms-grid-column: 1;
-ms-grid-column-span: 2;
-ms-grid-row: 2;
grid-column: span 2;
grid-row: 2/3;
}
#mainImg {
margin-bottom: 20px;
}
.textarea {
margin-top: 20px;
}
#full, #howto {
display:none;
}
.innerBox, .graphPanels {
flex: 0 0 100%;
}
}
@media only screen and (min-width: 991px) {
.pathText {
display: none;
}
.textarea {
margin-top: 128px;
height: 138px;
}
}
#graphHospitalBySex {
display: none;
}
@media only screen and (max-width: 525px) {
.selection {
width: 180px;
height: 50px;
}
.selection p {
margin-left: 27px;
}
#big {
height: 300px;
}
#descPanel {
-ms-grid-column: 1;
-ms-grid-column-span: 2;
-ms-grid-row: 2;
grid-column: span 2;
}
#logPanel {
-ms-grid-column-span: 2;
flex-wrap: wrap;
grid-column: span 2;
}
#btnPanel {
-ms-grid-row: 4;
}
#graphPanel {
-ms-grid-row: 3;
grid-column: span 2;
grid-row: 3/4;
}
.btn-success,
.btn-info {
margin: 5px 0px!important;
width: 100%!important;
}
}
@media only screen and (max-width: 1690px) {
p.fsel, h3.fsel {
font-size: 1.1vw!important;
}
h1.fsel{
font-size: 2vw!important;
}
.innerBox.fsel{
margin-left: 2px;
margin-right: 2px;
}
#full.fsel, #howto.fsel, #langToggle.fsel{
font-size: 0.8vw;
}
.graphPanels.fsel{
/*height: 40%!important;*/
/*flex: 0 0 46%!important;*/
margin: 2px!important;
}
#barDiv.fsel .axis text, #barDiv.fsel .barText{
font-size: 23px!important;
}
#trendData.fsel .trendX text,#trendData.fsel .trendY text,#trendData.fsel .xAxisTrendLabel,#trendData.fsel yAxisTrendLabel,#trendData2.fsel .trendX2 text,#trendData2.fsel .trendY2 text,#trendData2.fsel .xAxisTrendLabel2, yAxisTrendLabel2{
font-size: 15px;
}
.graphPanelsText p.fsel{
line-height: 3vh;
font-size: 1.3vh!important;
}
}
@media only screen and (max-width: 1200px) {
.dropdown {
/*height: 29px !important;*/
font-size: 0.9em !important;
}
}
@media only screen and (max-width: 1000px) {
#full, #howto, #langToggle {
margin-top:-10px !important;
}
}
.navbuttons {
padding:0px;
}
.navbuttons .btn-group{
padding:20px 0px;
}
@media only screen and (max-width: 768px) {
.boxes .parent, .boxes .parent:visited, .boxes .parent:focus, .boxes .parent:hover {
flex: 0 0 100%;
border: 3px solid #ccc;
border-radius: 10px;
margin: 10px;
text-decoration: none;
color: black;
}
.navbuttons a {
padding:10px 0px !important;
}
}
.info {
opacity: 0.3;
}
.info:hover{
cursor: pointer;
opacity:1;
}
.info:hover + .hiddenInfo{
display: block;
}
.hiddenInfo {
display: none;
}
</style>
</head>
<body vocab="http://schema.org/" typeof="WebPage">
<!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
<script>dataLayer1 = [];</script>
<script>dataLayer = [];</script>
<!-- End Google Tag Manager -->
<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TN3RPZ"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-TN3RPZ');</script>
<!-- End Google Tag Manager -->
<!-- Google Tag Manager DO NOT REMOVE OR MODIFY - NE PAS SUPPRIMER OU MODIFIER -->
<noscript><iframe title="Google Tag Manager" src="//www.googletagmanager.com/ns.html?id=GTM-TLGQ9K" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer1'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer1','GTM-TLGQ9K');</script>
<!-- End Google Tag Manager -->
<ul id="wb-tphp">
<li class="wb-slc">
<a class="wb-sl" href="#wb-cont">Skip to main content</a>
</li>
<li class="wb-slc">
<a class="wb-sl" href="#wb-info">Skip to "About government"</a>
</li>
</ul>
<header>
<div id="wb-bnr" class="container">
<section id="wb-lng" class="text-right">
<h2 class="wb-inv">Language selection</h2>
<ul class="list-inline margin-bottom-none">
<li><a lang="fr" href="https://sante-infobase.canada.ca/covid-19/securite-vaccins/">Français</a></li>
</ul>
</section>
<div class="row">
<div class="brand col-xs-5 col-md-4">
<a href="https://www.canada.ca/en.html"><img src="/src/GCWeb/assets/sig-blk-en.svg" alt=""><span class="wb-inv"> Government of Canada / <span lang="fr">Gouvernement du Canada</span></span></a>
</div>
<section id="wb-srch" class="col-lg-8 text-right">
<h2>Search</h2>
<form action="https://www.canada.ca/en/sr/srb.html" method="get" name="cse-search-box" role="search" class="form-inline">
<div class="form-group">
<label for="wb-srch-q" class="wb-inv">Search Canada.ca</label>
<input id="wb-srch-q" list="wb-srch-q-ac" class="wb-srch-q form-control" name="q" type="search" value="" size="34" maxlength="170" placeholder="Search Canada.ca">
<datalist id="wb-srch-q-ac">
</datalist>
</div>
<div class="form-group submit">
<button type="submit" id="wb-srch-sub" class="btn btn-primary btn-small" name="wb-srch-sub"><span class="glyphicon-search glyphicon"></span><span class="wb-inv">Search</span></button>
</div>
</form>
</section>
</div>
</div>
<nav class="gcweb-menu" typeof="SiteNavigationElement">
<div class="container">
<h2 class="wb-inv">Menu</h2>
<button type="button" aria-haspopup="true" aria-expanded="false"><span class="wb-inv">Main </span>Menu <span class="expicon glyphicon glyphicon-chevron-down"></span></button>
<ul role="menu" aria-orientation="vertical" data-ajax-replace="/src/ajax/sitemenu-v2-en.html">
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/jobs.html">Jobs and the workplace</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/immigration-citizenship.html">Immigration and citizenship</a></li>
<li role="presentation"><a role="menuitem" href="https://travel.gc.ca/">Travel and tourism</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/business.html">Business and industry</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/benefits.html">Benefits</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/health.html">Health</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/taxes.html">Taxes</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/environment.html">Environment and natural resources</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/defence.html">National security and defence</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/culture.html">Culture, history and sport</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/policing.html">Policing, justice and emergencies</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/transport.html">Transport and infrastructure</a></li>
<li role="presentation"><a role="menuitem" href="http://international.gc.ca/world-monde/index.aspx?lang=eng">Canada and the world</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/finance.html">Money and finances</a></li>
<li role="presentation"><a role="menuitem" href="https://www.canada.ca/en/services/finance.html">Science and innovation</a></li>
</ul>
</div>
</nav>
<nav id="wb-bc" property="breadcrumb">
<h2>You are here:</h2>
<div class="container">
<ol class="breadcrumb">
<li><a href="https://www.canada.ca/en.html">Canada.ca</a></li>
<li><a href="https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html">Coronavirus disease (COVID-19)</a></li>
<li><a href="https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html">Vaccines for COVID-19</a></li>
</ol>
</div>
</nav>
</header>
<main property="mainContentOfPage" id="main" class="container">
<div id="surveyIframe" style="background-color:#335075;width:100%;height:150px;position:fixed;bottom:0px;left:0px;z-index:100;">
<button type="button" class="mfp-close overlay-close" title="Close overlay" style="">×<span class="wb-inv"> Close survey overlay</span></button>
<iframe src="https://ca1se.voxco.com/SE/?st=dgKt%2FuQTAgrMcyZdP0fuwOOo%2BQPsqhn%2B4rx9ZweEmF4%3D&lang=EN" height="150" width="100%" frameborder="0" scrolling="no" style="position:fixed;bottom:0px;z-index:100"></iframe>
</div>
<h1>Reported side effects following COVID-19 vaccination in Canada</h1>
<div class="col-md-12" style="padding: 0">
<div class="btn-group btn-group-lg btn-group-justified" style="padding:20px 0px;">
<a class="btn btn-default" role="button" href="/covid-19/vaccine-safety/summary.html">Summary</a>
<a class="btn btn-primary active" role="button" href="#">Detailed report</a>
<a class="btn btn-default" role="button" href="/covid-19/vaccine-safety/utd.html">Understanding the data</a>
<a class="btn btn-default" role="button" href="/covid-19/vaccine-safety/archive/">Archived reports</a>
</div>
</div>
<p>This page will be updated next on January 20, 2023 at noon EST.</p>
<!-- <section class="alert alert-info">-->
<!-- <p style="font-weight:bold;">Changes to the update schedule</p>-->
<!-- <p>Please note that due to the holidays, the May 27 report will be published on May 30, 2022.</p>-->
<!--</section>-->
<p class="h3">This page was last updated on December 22, 2022 with data up to and including <span class="dateToShort nowrap">MMM DD, YYYY</span>.</p>
<h2>On this page</h2>
<ul>
<li><a href="#a1" class="anchor">What you need to know</a></li>
<li><a href="#howToReport" class="anchor">How to report an adverse event</a></li>
<li><a href="#a3" class="anchor">Reporting trends</a></li>
<li><a href="#a4" class="anchor">Adverse event following immunization reports by vaccine name</a></li>
<li><a href="#a5" class="anchor">Adverse event following immunization reports by age and sex</a></li>
<li><a href="#a6" class="anchor">Most common adverse events reported following immunization</a></li>
<li><a href="#specialInterest" class="anchor">Adverse events of special interest, safety signals and deaths</a></li>
<li><a href="#acknowledgements" class="anchor">Acknowledgements, suggested citation, and related links</a></li>
</ul>
<h2 id="a1">What you need to know <small><!--data reported--> up to and including <span class="dateToShort">MMM DD, 2021</span></small></h2>
<div class="boxes">
<div class="parent">
<a href="#newSafetyIssues" data-figure="1" class="anchor box" style="display: flex; align-items: center;">
<div class="mrgn-tp-lg mrgn-bttm-lg" style="width: 100%;">
<p class="h2"><span class="safetySignals">No new safety signals have been identified in Canada</span></p>
</div>
</a>
</div>
<div class="parent">
<a href="#a3" data-figure="1" class="anchor box" style="display: flex; align-items: center;">
<div class="mrgn-tp-xl mrgn-bttm-lg" style="width: 100%">
<p class="h2"><span class="totalDoses">56,151,862</span></p>
<p>Total doses administered up to and including December 9, 2022</p>
</div>
</a>
</div>
<div class="parent">
<a href="#a3" data-figure="1" class="anchor box" style="display: flex; align-items: center;">
<div class="mrgn-tp-lg mrgn-bttm-lg" style="width: 100%">
<p class="h2"><span class="totalAEFIs">17,982</span></p>
<p>Total adverse event following immunization reports</p>
<p class="h2"><small>(<span class="percentageDosesAdminTotal">0.032%</span> of all doses administered)</small></p>
</div>
</a>
</div>
<div class="parent">
<a href="#seriousNonSerious" data-figure="1" class="anchor box" style="display: flex; align-items: center;">
<div style="margin-top: 60px;" class="mrgn-bttm-lg">
<p class="h2"><span class="totalNonseriousAEFIs">13,307</span></p>
<p>Total adverse event following immunization reports that were non-serious</p>
<p class="h2"><small>(<span class="percentageDosesAdminNonSerious">0.024%</span> of all doses administered)</small></p>
</div>
</a>
</div>
<div class="parent">
<a href="#seriousNonSerious" data-figure="1" class="anchor box" style="display: flex; align-items: center;">
<div style="margin-top: 60px;" class="mrgn-bttm-lg">
<p class="h2"><span class="totalSeriousAEFIs">4,675</span></p>
<p>Total adverse event following immunization reports that were serious</p>
<p class="h2"><small>(<span class="percentageDosesAdminSerious">0.008%</span> of all doses administered)</small></p>
</div>
</a>
</div>
</div>
<ul>
<li>No new safety signals have been identified during this reporting period.</li>
<li>Evidence indicates that the benefits of COVID-19 vaccines continue to outweigh the risks of the disease.</li>
<li>Health Canada, the Public Health Agency of Canada (PHAC), the provinces and territories, and manufacturers continue to closely monitor the safety of COVID-19 vaccines. We’ll respond to any safety issues right away and will inform Canadians about any risks that arise in Canada.</li>
<li>Of the <strong><span class="totalAEFIs"></span></strong> individual reports (<span style="font-weight: bold;"><span class="percentageDosesAdminTotal"></span> of all doses administered</span>), <strong><span class="totalSeriousAEFIs"></span></strong> were considered serious (<span style="font-weight: bold;"><span class="percentageDosesAdminSerious"></span> of all doses administered</span>).
<ul>
<li>Of the 53,064 reports, 225 followed vaccination with a bivalent COVID-19 vaccine (0.0036% of Bivalent COVID-19 doses administered). 51 (0.0008%) were considered serious.</li>
</ul>
</li>
<!--<li>20 COVID-19 adverse event reports are following vaccination with Moderna Spikevax Bivalent (Original/Omicron BA.1) COVID-19 vaccine (0.001% of Moderna Spikevax Bivalent (Original/Omicron BA.1) COVID-19 doses administered). Of these 20 reports, 7 were considered serious and all 20 are captured under Moderna Spikevax throughout this report. As of October 14, 2022 we have not received any adverse event reports following vaccination with the Pfizer-BioNTech Comirnaty Bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine.</li>-->
</ul>
<h2 id="howToReport">How to report an adverse event</h2>
<p>If you experience an adverse event following immunization with a COVID-19 vaccine in Canada, please contact your healthcare provider. Learn more about <a href="https://www.canada.ca/en/public-health/services/immunization/reporting-adverse-events-following-immunization/form.html">reporting adverse events</a>.</p>
<h2 id="a3">Reporting trends</h2>
<ul>
<li>The information on this page reflects detailed case information data from the Public Health Agency of Canada’s Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) and Health Canada’s Canada Vigilance program. Doses administered used for reporting rate calculations have been adjusted to account for the delay between vaccination and reporting. The data on this page may undergo changes as more information about cases becomes available.</li>
<li>There have been a total of <span class="totalAEFIs" style="font-weight: bold;"></span> reports (<span style="font-weight: bold;"><!--<span class="coveragePer100KTotal"></span> -->55.6 reports per 100,000 doses administered</span>) up to and including <span style="font-weight: bold;" class="dateToShort nowrap"></span>. Of the <span class="totalAEFIs" style="font-weight: bold;"></span> reports, <span class="totalSeriousAEFIs" style="font-weight: bold;"></span> were considered serious (<span style="font-weight: bold;"><!--<span class="coveragePer100KSerious">-->11.0</span> reports per 100,000 doses administered</span>). Overall, the rate of serious reports has remained low. Figure 1 below shows the number and rate of COVID-19 adverse event reports by reporting period, as well as the cumulative number of reports.</li>
</ul>
<div id="section1" class="section">
<div id="figure1div" class="figure">
<h3>Figure 1.
<label for="figure1-dropdown-measure" class="hidden">Choose a measure:</label>
<span class="nowrap"><select id="figure1-dropdown-measure" class="dropdown">
<option value="monthly">Number</option>
<option value="rate">Rate</option>
<option value="monthly&rate">Number and rate</option>
<option value="total">Cumulative number</option>
</select></span>
<span style="display:none" class="nowrap"><select id="figure1-dropdown-measure_2" class="dropdown">
<option value="number">number</option>
<option value="rate">rate</option>
</select></span>
of COVID-19 vaccine adverse event reports received for
<select id="figure1-dropdown-measure3" class="dropdown">
<option value="all">all people</option>
<option value="18plus">people 18 years and older</option>
<option value="12to17">people 12 to 17 years</option>
<option id="childrenFig1" value="5to11">people 5 to 11 years</option>
<option value="0to4">people 0 to 4 years</option>
</select>
and total doses administered in a 4-week reporting period, up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="totalAEFIs nChange"></span>)<!--nChange-->
</h3>
<span id="note"></span>
<svg class="chart barVertStacked" id="figure1"></svg>
<details>
<summary>Notes</summary>
<ul>
<li style="font-size: 15px; line-height: 120%;">Although the cumulative number of adverse event reports continues to increase over time, so does the number of doses administered. Up to and including <span class="dateToShort">MMM DD, 2021</span> all adverse event reports represented 0.056% of all doses administered.</li>
<li style="font-size: 15px; line-height: 120%;">The shaded area represents a period of time (lag time) where there may be delays in receiving and processing reporting forms. There may also be delays in receiving data on doses administered.</li>
<li style="font-size: 15px; line-height: 120%;">Please note that as of June 27, 2022, this figure reflects counts and rates over a 4 week period. This is due to changes in reporting schedules.</li>
<li style="font-size: 15px; line-height: 120%;">Information on doses administered by age group was only available starting April 23, 2021 for those aged 12 and older, starting November 27, 2021 for those aged 5 to 11 years, and starting July 17, 2022 for those under the age of 5. Rates of adverse event reports and doses administered by age group are not reported before these dates.</li>
</ul>
</details>
</div>
<details id="figure1aDetails" style="display:block">
<summary>Figure 1: Text Description</summary>
<h4 style="font-weight:bold;" class="text-left"><!--Total & New--> Number of <!--<span class="vaccine-type2"></span>--> COVID-19 adverse event reports received for all people up to and including <span class="dateToShort"></span> (n=<span class="totalAEFIs nChange">53,064</span>)</h4>
<div class="table-responsive">
<table id="figure1aTable" class="descTable table table-striped table-hover table-bordered">
<thead>
<tr>
<th scope="col">Reporting period</th>
<th scope="col">Non-serious <span class="nowrap">reports</span>-all</th>
<th scope="col">Serious <span class="nowrap">reports</span>-all</th>
<th scope="col">Cumulative non-serious <span class="nowrap">reports</span>-all</th>
<th scope="col">Cumulative serious <span class="nowrap">reports</span>-all</th>
<th scope="col">Cumulative number of doses administered-all<sup>1</sup></th>
<th scope="col">Number of doses administered-all<sup>1</sup></th>
<th scope="col">Non-serious reporting rate-all<sup>2</sup></th>
<th scope="col">Serious reporting rate-all<sup>2</sup></th>
<th scope="col">Reporting rate-all<sup>2</sup></th>
<th scope="col">Non-serious <span class="nowrap">reports</span>-18plus</th>
<th scope="col">Serious <span class="nowrap">reports</span>-18plus</th>
<th scope="col">Cumulative non-serious <span class="nowrap">reports</span>-18plus</th>
<th scope="col">Cumulative serious <span class="nowrap">reports</span>-18plus</th>
<th scope="col">Cumulative number of doses administered-18plus<sup>1</sup></th>
<th scope="col">Number of doses administered-18plus<sup>1</sup></th>
<th scope="col">Non-serious reporting rate-18plus<sup>2</sup></th>
<th scope="col">Serious reporting rate-18plus<sup>2</sup></th>
<th scope="col">Reporting rate-18plus<sup>2</sup></th>
<th scope="col">Non-serious <span class="nowrap">reports</span>-12to17</th>
<th scope="col">Serious <span class="nowrap">reports</span>-12to17</th>
<th scope="col">Cumulative non-serious <span class="nowrap">reports</span>-12to17</th>
<th scope="col">Cumulative serious <span class="nowrap">reports</span>-12to17</th>
<th scope="col">Cumulative number of doses administered-12to17<sup>1</sup></th>
<th scope="col">Number of doses administered-12to17<sup>1</sup></th>
<th scope="col">Non-serious reporting rate-12to17<sup>2</sup></th>
<th scope="col">Serious reporting rate-12to17<sup>2</sup></th>
<th scope="col">Reporting rate-12to17<sup>2</sup></th>
<th scope="col">Non-serious<span class="nowrap">reports</span>-5to11</th>
<th scope="col">Serious <span class="nowrap">reports</span>-5to11</th>
<th scope="col">Cumulative non-serious <span class="nowrap">reports</span>-5to11</th>
<th scope="col">Cumulative serious <span class="nowrap">reports</span>-5to11</th>
<th scope="col">Cumulative number of doses administered-5to11<sup>1</sup></th>
<th scope="col">Number of doses administered-5to11<sup>1</sup></th>
<th scope="col">Non-serious reporting rate-5to11<sup>2</sup></th>
<th scope="col">Serious reporting rate-5to11<sup>2</sup></th>
<th scope="col">Reporting rate-5to11<sup>2</sup></th>
<th scope="col">Non-serious<span class="nowrap">reports</span>-0to4</th>
<th scope="col">Serious <span class="nowrap">reports</span>-0to4</th>
<th scope="col">Cumulative non-serious <span class="nowrap">reports</span>-0to4</th>
<th scope="col">Cumulative serious <span class="nowrap">reports</span>-0to4</th>
<th scope="col">Cumulative number of doses administered-0to4<sup>1</sup></th>
<th scope="col">Number of doses administered-0to4<sup>1</sup></th>
<th scope="col">Non-serious reporting rate-0to4<sup>2</sup></th>
<th scope="col">Serious reporting rate-0to4<sup>2</sup></th>
<th scope="col">Reporting rate-0to4<sup>2</sup></th>
</tr>
</thead>
</table>
<p><sup>1</sup> Doses administered used for rate calculations have been adjusted to account for the delay between vaccination and reporting.</p>
<p><sup>2</sup> Reporting rate per 100,000 doses administered.</p>
</div>
</details>
</div>
<div id="section2" class="section">
<h2 id="a4">Adverse event following immunization reports by vaccine name</h2>
<ul>
<li>Figure 2 shows the breakdown of reports by vaccine name. For doses administered by vaccine type, please visit the <a href="https://health-infobase.canada.ca/covid-19/vaccination-coverage/">vaccination coverage report</a>.</li>
<li>Higher rates of non-serious adverse event reports are observed for each vaccine. Serious report rates remain low. Currently, rates of adverse event reports following the first dose are higher than after subsequent doses.</li>
<li>The data for subsequent doses do not take into account which vaccine an individual received for previous doses. Generally, non-serious adverse event reports are consistent with information provided in the <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines.html">vaccine product pages.</a></li>
<li>Notes:
<ul>
<li>129 of the 53,064 COVID-19 adverse event reports (0.24%), involved people who received an influenza vaccine and a COVID-19 vaccine on the same day. These events have been closely monitored, and no new safety concerns have been identified.</li>
<li>Of the 53,064 reports, 225 followed vaccination with a bivalent COVID-19 vaccine (0.0036% of Bivalent COVID-19 doses administered). 51 (0.0008%) were considered serious.</li>
</ul>
</li>
</ul>
<h3>Figure 2.
<label for="figure2-dropdown-measure" class="hidden">Choose a measure:</label>
<span class="nowrap"><select id="figure2-dropdown-measure" class="dropdown">
<option value="number">Number</option>
<option id="rate" value="rate">Rate</option>
</select></span> of adverse event reports received for
<select id="figure2-dropdown-measure2" class="dropdown">
<option value="all">all people</option>
<option value="18plus">people 18 years and older</option>
<option id="youth" value="12to17">people 12 to 17 years</option>
<option id="children" value="5to11">people 5 to 11 years</option>
<option id="noRate" value="0to4">people 0 to 4 years</option>
</select> by vaccine name and
<select id="figure2-dropdown-measure3" class="dropdown">
<option value="Total">all doses</option>
<option value="Dose 1">dose 1</option>
<option value="Dose 2">dose 2</option>
<option value="Dose 3">dose 3</option>
<option value="Dose 4+">dose 4+</option>
</select>
up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="nChange2"></span>)</h3>
<div id="figure2div" class="figure">
<svg class="chart barVertStacked" id="figure2"></svg>
</div>
<details>
<summary>Notes</summary>
<span style="font-size: 13px; font-weight:bold;">Total includes reports that did not specify dose number.</span>
</details>
<details>
<summary>Figure 2: Text Description</summary>
<div class="table-responsive">
<h4>Number and rate (per 100,000 doses administered) of adverse event reports received for all people by vaccine name and dose number, up to and including <span class="dateToShort">MMM DD, 2021</span> (n=52,405<!--<span class="totalAEFIs"></span>-->)</h4>
<table id="figure2Table" class="descTable table table-striped table-hover table-bordered" style="margin-top:40px;">
<thead>
<tr>
<th scope="col">Vaccine name</th>
<th scope="col">Non-serious reports-all<sup>2</sup></th>
<th scope="col">Serious reports-all<sup>2</sup></th>
<th scope="col">Total reports-all<sup>2</sup></th>
<th scope="col">Non-serious reporting rate-all<sup>3</sup></th>
<th scope="col">Serious reporting rate-all<sup>3</sup></th>
<th scope="col">Total reporting rate-all<sup>3</sup></th>
<th scope="col">Total number of doses administered-all</th>
<th scope="col">Non-serious reports-18plus<sup>2</sup></th>
<th scope="col">Serious reports-18plus<sup>2</sup></th>
<th scope="col">Total reports-18plus<sup>2</sup></th>
<th scope="col">Non-serious reporting rate-18plus<sup>3</sup></th>
<th scope="col">Serious reporting rate-18plus<sup>3</sup></th>
<th scope="col">Total reporting rate-18plus<sup>3</sup></th>
<th scope="col">Total number of doses administered-18plus<sup>4</sup></th>
<th scope="col">Non-serious reports-12to17<sup>2</sup></th>
<th scope="col">Serious reports-12to17<sup>2</sup></th>
<th scope="col">Total reports-12to17<sup>2</sup></th>
<th scope="col">Non-serious reporting rate-12to17<sup>3</sup></th>
<th scope="col">Serious reporting rate-12to17<sup>3</sup></th>
<th scope="col">Total reporting rate-12to17<sup>3</sup></th>
<th scope="col">Total number of doses administered-12to17</th>
<th scope="col">Non-serious reports-5to11<sup>2</sup></th>
<th scope="col">Serious reports-5to11<sup>2</sup></th>
<th scope="col">Total reports-5to11<sup>2</sup></th>
<th scope="col">Non-serious reporting rate-5to11<sup>3</sup></th>
<th scope="col">Serious reporting rate-5to11<sup>3</sup></th>
<th scope="col">Total reporting rate-5to11<sup>3</sup></th>
<th scope="col">Total number of doses administered-5to11</th>
<th scope="col">Non-serious reports-0to4<sup>2</sup></th>
<th scope="col">Serious reports-0to4<sup>2</sup></th>
<th scope="col">Total reports-0to4<sup>2</sup></th>
<th scope="col">Non-serious reporting rate-0to4<sup>3</sup></th>
<th scope="col">Serious reporting rate-0to4<sup>3</sup></th>
<th scope="col">Total reporting rate-0to4<sup>3</sup></th>
<th scope="col">Total number of doses administered-0to4</th>
</tr>
</thead>
</table>
<!--<sup>*</sup>The number of dose 1 doses administered for certain vaccines have decreased since last report due to data updates.-->
<p><sup>1</sup>Includes reports that did not specify dose number.</p>
<p><sup>2</sup>Includes reports that contain information on more than one vaccine name.</p>
<p><sup>3</sup>Reporting rate per 100,000 doses administered.</p>
</div>
</details>
</div>
<div id="a5" class="section">
<h2 id="ageSex">Adverse event following immunization reports by age and sex</h2>
<h4>Age differences</h4>
<ul>
<li>The rate of adverse event reports was highest among the <strong>40 to 49 year age group</strong> (81.9 reports per 100,000 doses administered), followed by those in the 30-39 year age group (70.2 reports per 100,000 doses administered).</li>
<li>The rate of adverse event reports was lowest in the <strong>5 to 11 year age group.</strong></li>
</ul>
<h4>Sex differences</h4>
<ul>
<li>Overall, most adverse event reports were from females (72.6%). The reporting rate for <b>females</b> was <b>75.6 reports per 100,000 doses administered</b>, compared to <b>30.5 per 100,000 doses administered</b> for <b>males</b>. However, within the youngest age groups (<18 years of age) the reporting rate is similar in males and females, or slightly higher in males.
<ul>
<li>This may be due to differences in health care seeking behaviour (for example, reporting adverse events) as well as biological differences between females and males.</li>
</ul>
<li>The higher proportion and rate of adverse event reports for females has been observed in the <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm">United States</a>, the <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00224-3/fulltext#seccestitle130">United Kingdom</a>, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875740/">Israel</a>, and <a href="https://www.medrxiv.org/content/10.1101/2021.03.23.21253433v1">other countries</a>.</li>
<ul>
<li>Health Canada, PHAC, and provincial and territorial public health authorities will continue to monitor but have not identified this as a safety issue.</li>
</ul>
</ul>
<h3>Figure 3. <span class="nowrap"><select id="figure3-dropdown-measure2" class="dropdown">
<option value="number">Number</option>
<option value="rate">Rate</option>
</select></span> of adverse event reports received by
<select id="figure3-dropdown-measure" class="dropdown">
<option value="ageGroup">age group</option>
<option value="both">age group and sex</option>
</select>
up to and including <span class="dateToShort">MMM DD, 2021</span> (n=<span class="totalAEFIs"></span>)</h3>
<div id="figure3div" class="figure">
<svg class="chart barGrouped trend" id="figure3"></svg>
<!--<p style="font-size: 15px; line-height: 120%;"><strong>Data notes:</strong> Reports of 11-year-olds who received the Pfizer-BioNtech Comirnaty COVID-19 vaccine dose for individuals 12 years of age and older before the pediatric dose was authorized were previously included in the 12 to 17 year age group. As of December 17, 2021, they are included in the 5 to 11 age group, regardless of dosage amount. Reports of 4-year-olds who received the Pfizer-BioNtech Cominarty COVID-19 vaccine dose for individuals 5 to 11 years of age are included in the 0 to 4 age group.</p>-->
<details id="figure3aDetails">
<summary>Figure 3: Text Description</summary>
<div class="table-responsive">
<h4 class="text-left">Number and rate (per 100,000 doses administered) of adverse event reports received by age group and sex up to and including <span class="dateToShort"></span> (n=<span class="totalAEFIs"></span>)</h4>
<table id="figure3Table" class="descTable table table-striped table-hover table-bordered">
<thead>
<tr>
<th scope="col">Age group</th>
<th scope="col">Total</th>
<th scope="col">Male</th>
<th scope="col">Female</th>
<th scope="col">Other</th>